Ensysce wins $14M federal grant for lead pain therapy

seekingalpha08-27

Nano-cap biotech Ensysce Biosciences (NASDAQ:ENSC) surged ~62% in the premarket trading on Tuesday after receiving a $14M grant from the U.S. government to support investigations into its lead pain ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2462621911?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/471399337/image_471399337.jpg","is_english":true,"pubTime":"2024-08-27 20:43","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2462621911","market":"sh","top_or_hot":-1,"title":"Ensysce wins $14M federal grant for lead pain therapy","media":"seekingalpha","content":"<div>\n<p>Nano-cap biotech Ensysce Biosciences (NASDAQ:ENSC) surged ~62% in the premarket trading on Tuesday after receiving a $14M grant from the U.S. government to support investigations into its lead pain ...</p>\n\n<a href=\"https://seekingalpha.com/news/4144105-ensysce-stock-jumps-14m-federal-grant\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ensysce wins $14M federal grant for lead pain therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnsysce wins $14M federal grant for lead pain therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-27 20:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4144105-ensysce-stock-jumps-14m-federal-grant><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nano-cap biotech Ensysce Biosciences (NASDAQ:ENSC) surged ~62% in the premarket trading on Tuesday after receiving a $14M grant from the U.S. government to support investigations into its lead pain ...</p>\n\n<a href=\"https://seekingalpha.com/news/4144105-ensysce-stock-jumps-14m-federal-grant\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://seekingalpha.com/news/4144105-ensysce-stock-jumps-14m-federal-grant","article_id":"2462621911","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/471399337/image_471399337.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2462621911","pubTimestamp":1724762613,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Nano-cap biotech Ensysce Biosciences  surged ~62% in the premarket trading on Tuesday after receiving a $14M grant from the U.S. government to support investigations into its lead pain therapy candidate PF614-MPAR. The funding issued by the National Institutes of Health  and the National Institute on Drug Abuse  will be available over approximately three years, allowing the company to complete a Phase 1b trial for PF614-MPAR. Ensysce  said.  Named PF614-MPAR-102, the trial builds on data from the company’s initial Phase 1 trial, PF614-MPAR-101, for the drug. Both PF614-MPAR-102 and PF614-MPAR-101 are expected to help the company introduce PF614-MPAR as the first opioid therapy with oral overdose protection, Ensysce  said. The latest funding adds to $26M in federal grants allocated to the company for its Multi-Pill Abuse Resistance  platform and its opioid use disorder  programs.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ENSC":"Ensysce Biosciences Inc."},"translate_title":"Ensysce赢得1400万美元联邦拨款用于铅疼痛治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENSC":1},"content_text":"Nano-cap biotech Ensysce Biosciences (NASDAQ:ENSC) surged ~62% in the premarket trading on Tuesday after receiving a $14M grant from the U.S. government to support investigations into its lead pain therapy candidate PF614-MPAR. The funding issued by the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA) will be available over approximately three years, allowing the company to complete a Phase 1b trial for PF614-MPAR. Ensysce (ENSC) said.  Named PF614-MPAR-102, the trial builds on data from the company’s initial Phase 1 trial, PF614-MPAR-101, for the drug. Both PF614-MPAR-102 and PF614-MPAR-101 are expected to help the company introduce PF614-MPAR as the first opioid therapy with oral overdose protection, Ensysce (ENSC) said. The latest funding adds to $26M in federal grants allocated to the company for its Multi-Pill Abuse Resistance (MPAR) platform and its opioid use disorder (OUD) programs.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2462621911"}